ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0917

Role of Mutual Information Profile Shifts in Assessing the Pathogenicity of Mutations on Protein Functions: The Case of Pyrin Mutations in Familial Mediterranean Fever
Abstract Number: 1238

Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica
Abstract Number: 2052

Role of Scleroderma/myositis-related Autoantibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 410 Patients from a Single Referral Center
Abstract Number: 0048

Role of the Chemokine CCL22 in Rheumatoid Arthritis Development
Abstract Number: 0806

Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events
Abstract Number: 0784

RUNX1 Is Expressed in a Subpopulation of Dermal Fibroblasts and Is Increased with Systemic Sclerosis Disease Severity
Abstract Number: 1014

Rural-dwelling Patients with Rheumatoid Arthritis or Those with Lower Income Are More Likely to Be Admitted for Myocardial Infarction in the U.S. and Have Worse Outcomes
Abstract Number: 0177

Rural-urban Disparities in the Myocardial Infarction Hospitalizations in People with Systemic Lupus Erythematosus in the US
Abstract Number: 0737

Rurality and Delayed Diagnosis of Giant Cell Arteritis – a Single Center Experience
Abstract Number: 1864

S-4321, a Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
Abstract Number: 1681

Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study
Abstract Number: 1460

Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
Abstract Number: 1979

Safety and Effectiveness of Immune Checkpoint Inhibitor Therapy in Patients with Pre-existing Autoimmune Disease
Abstract Number: 1734

Safety and Efficacy Data from a Phase I Trial of Umbilical Lining-Derived Stem Cells (ULSC) in Adult Dermatomyositis/Polymyositis
Abstract Number: 1733

Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].